Introduction
Activating mutations in the mitogen-activated protein kinase (p42/p44 MAPK) pathway represent an important and unsolved therapeutic target in multiple solid tumors (1) (2) (3) (4) (5) .
The combined activating mutations in KRAS, BRAF, NRAS and HRAS, occur frequently in malignant melanomas (64%), carcinomas of the pancreas (73%), colon (51%) and lung (19%) 1 .
Inhibitors of MEK1 and MEK2 have long shown promise as targeted therapies for tumors dependent on these activating mutations in the MAPK pathway, but so far they have disappointed with their lack of clinical activity. The failure is presumed to be due to a narrow therapeutic window, constrained by the essential nature of the p42/p44 MAPK pathway in non-tumor cells. The elusive goal has been a clinically active MEK inhibitor that combines sustained high level of MEK inhibition in tumors with limited systemic toxicity due to MEK inhibition in non targeted organs. We hypothesize that the preferred pharmacokinetic profile for a MEK inhibitor would combine prolonged exposure and a low Cmax (peak concentration) to Ctrough (trough concentration) ratio, delivering sustained levels of sufficient dose and potentially avoiding toxicities that might result from high transient peak exposure. With previous MEK inhibitors as well as several new MEK inhibitors currently being evaluated in early clinical trials, pharmacokinetic profiles have generally been reported to have relatively high Cmax and short half-life in blood, requiring twice-daily dosing for activity (6) (7) (8) (9) (10) . A repeated high Cmax may be a concern for systemic toxicity, while a short circulating half-life may be insufficient to achieve the necessary sustained pathway inhibition in tumors.
Here we describe GSK1120212 (JTP-74057), an allosteric inhibitor of MEK1 and MEK2 activity that has shown promising early clinical activity in tumors with activating mutations in BRAF (ASCO 2010). GSK1120212 is orally bioavailable, potent, specific and has a long circulating half life with low Cmax to Ctrough ratio. We observe potent inhibition of ERK phosphorylation in all cell lines tested and cell growth inhibition among most cancer cell lines with activating mutations in the MAPK pathway. In addition to inhibiting MEK dependant ERK phosphorylation, GSK1120212 inhibits MEK1/2 activation by preventing Raf phosphorylation of MEK on S217 (for MEK1). Finally, we observed significant growth inhibition in multiple tumor xenografts, and particularly in those harboring activating mutations in BRAF or KRAS.
Materials/Methods

MEK1 Enzyme Assays:
Inhibitors were dissolved in DMSO and present at final concentrations of 0.015 nm to 5000 nM with a final DMSO concentration 2.5%. Activated MEK (pp-MEK) assays contained: 40 µM Millipore Cat) and spun 5x with 10x volume dilutions for buffer exchange to effectively remove GSK1120212 and ATP (reduced to 50 pM and 5 nM, respectively). SB590885 was maintained at 1 µM throughout buffer exchange. MEK1 kinase assay was carried out in buffer containing 20 mM Hepes pH 7.2, 0.15 mg/ml BSA, 10 mM MgCl 2 , 0.8 mM CHAPS (Sigma), and 1 mM TCEP (Thermo), using kinase-dead ERK2 as substrate with 33 P-γATP detection in TCA precipitation filter binding assay. MEK kinase reactions were stopped after 40mins by transferring 30μls of reaction mixture to a Durapore 0.45μm filters plates (Millipore) containing 12.5% TCA. Filters were dried and read with liquid scintilant on a TopCount (Perkin Elmer). Concentration response data were analyzed by nonlinear regression using a 3 parameter equation with the bottom set to zero for IC 50 estimation using GraphPad Software. Rates of ERK2 phosphorylation were determined as measures of relative activity.
Immunoblotting
Cell lysates were prepared using RIPA buffer (TEKnova) supplemented with protease (ROCHE) and phosphatase inhibitor cocktails (SIGMA), immunoblotted according to
Research. and phospho-C-Raf(ser338) (56A6) (Cell Signaling Technologies). Secondary antibodies included goat anti-mouse and -rabbit (Odyssey).
Cell Culture and Proliferation Assays
Cell lines were obtained from ATCC and grown in the recommended media at 37ºC, 5% CO 2 in a humidified incubator. Cells were seeded in triplicate 96 well microtitre plates at 1000 cells per well. GSK1120212 dissolved in DMSO or negative control (0.1% DMSO)
were added the following day and one plate was harvested with 50μl of CellTiter-Glo (Promega) for a time 0 (T=0) measurement. Remaining duplicate cell plates were typically incubated for 72 hours. Cells were then lysed with 50μl CellTiter-Glo, and chemiluminescent signal was read on the Wallac EnVision 2100 plate reader. All data were normalized to signal at time of compound addition (T=0). Curves were analyzed using the XLfit (IDBS Ltd.) tool, fitting to a 4-parameter curve to determine the gI 50 (concentration of 50% growth inhibition relative to T=0 and Ymax values), the gIMaximum (concentration giving maximum growth inhibition), and the Ymin (bottom of the four-parameter curve at gI-Maximum). Based on Ymin value we defined the maximum biological response for each cell line as 'cytotoxic' (a Ymin <90% reflecting a net-cell decrease), 'cytostatic' (Ymin= 90-200%, where cells undergo 1 or fewer complete divisions), or 'resistant' (Ymin>200%).
Site Specific Analysis of MEK phosphorylation by Mass Spectrometry
For cellular studies, endogenous MEK1 was immunoprecipitated from 1mg of whole cell lysate with a MEK1 (61B12) antibody and protein G beads. For in vitro kinase reactions, 7μM recombinant MEK1 was preincubated with vehicle or GSK1120212 (10 μM) for 30mins, and treated with an equal volume containing constitutively active C-Raf (50 nM, Millipore) for 120mins in kinase buffer (20mM MOPS, 0.05mg/ml BSA,0.01% Tween-20,10mMMgCl 2 , 5mM EGTA, 1mM DTT). Reactions were quenched by adding LDS Gel bands corresponding to endogenous MEK1 (immunoprecipitated) or recombinant MEK1 (kinase reaction) were excised, reduced, alkylated and digested over night with trypsin (Promega). After organic extraction, samples were injected on an Agilent 1100 nanoLC system. The nanoLC was interfaced to a LTQ-Orbitrap-XL mass spectrometer (ThermoFisher). Tryptic peptides were separated on a Dionex 100um RP-PSDVB monolithic column using a gradient of 0-30% acetonitrile/0.2% formic acid over 40 minutes. MS-based peptide sequencing was accomplished by tandem mass spectrometry using either data dependent LC-MS/MS or by targeted MS/MS sequencing of selected precursors. Uninterpreted tandem MS spectra were searched for protein matches against an in-house protein sequence database using Mascot (Matrix Science).
Alternatively, selected MS/MS spectra were manually interpreted to determine the site of phosphorylation within a specific peptide. Apparent phosphorylation stoichiometry was determined from the area under the LC-MS peaks corresponding to the phosphorylated form(s) of the peptide and the unphosphorylated counterpart.
Stoichiometry was calculated using the formula 
Pharmacokinetic (PK) Analysis
For mouse PK studies, tumor-bearing mice were euthanized at specified timepoints post dose and blood was drawn and combined immediately with an equal volume water to hemolyze the sample. Brains were harvested, flash frozen on dry ice, and weighed (with minimal handling to prevent tissues from thawing). 
Pharmacodyamic Measurement of p-ERK levels in blood and brain tissues
Tissues were harvested and homogenized using Medimachine (BD Bioscience) with 1 ml of lysis buffer (25 mM Tris-HCl (pH 7.5), 2 mM EDTA (pH 8.0), 2 mM EGTA (pH 8.0), 1% Triton X-100, 0.1% SDS, 50 mM Na--glycerol phosphate, 2 mM Na 3 VO 4 , 4 mM Napyrophosphate, 2x phosphatase inhibitor cocktail), and kept on ice. Following homogenization of all samples, homogenates were centrifuged at 14,000 rpm for 15 min at 4°C. Clarified lysates were flash frozen for later analysis. All samples were analyzed with a duplex ELISA (MescoScale Discovery) measuring total ERK1/2 and phospho-ERK1/2 according to manufacturer's instructions. Plates were read on MSD.SI6000. 
Immunohistochemistry
Results:
GSK1120212 inhibits MEK1 and MEK2 in enzymatic and cellular assays GSK1120212 (JTP-74057) (Fig. 1A) was identified during an extensive lead optimization campaign of hits from an earlier cellular screen for inducers of p15 INK4B and p27
Kip1/CDKN1B
; GSK1120212 and the related JTP70902 were subsequently confirmed to be a
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on July Fig. 3 ).The gradual increase in MEK1/2 and Raf phosphorylation, evident at later timepoints, and detected by immunoblotting is consistent with reports for other allosteric MEK1/2 inhibitors and is attributed to inhibition of a negative feedback mechanism involving Sprouty and Dual Specificity Phosphatases (DUSP) (18) . Taken together these results suggest that besides inhibiting MEK phosphorylating ERK1/2, in some cells GSK1120212 is partially inhibiting the activating phosphorylation of MEK by Raf.
GSK1120212 inhibits activating phosphorylation of MEK on S217.
We further investigated the effect of GSK1120212 on the activation of MEK in an in vitro assay, examining MEK1 phosphorylation by ftMSMS. Previous studies indicated that MEK1 is maximally activated upon dual phosphorylation of S217 and S221, with the mono-phosphorylated proteins being only fractionally activated (19) phosphorylation of MEK1 S217 by either C-Raf (Fig.2A) or B-Raf (data not shown) but had no effect on S221 phosphorylation.
We then attempted to determine the relative activity of p-MEK1(S221) compared with the pp-MEK1. MEK1 was activated with B-Raf in the presence or absence of GSK1120212 for 2hrs, compound was removed by repeated washes (in the presence of a B-Raf inhibitor SB590885A to prevent further activation), a fraction of protein was set aside for MS-analysis confirmation of phosphorylation, and finally the relative MEK1 kinase activities were compared for the rate of ERK2 phosphorylation. These results confirmed that p-MEK1(S221) was 32-fold more active than unphosphorylated MEK1 (u-MEK), but only fractionally as active (1/83-fold) as pp-MEK1 ( Supplementary Fig.4 A) .
Significantly, we also observed that the IC50 for GSK1120212 was at least 6-fold lower for purified p-MEK1(S221) compared to pp-MEK1 (Supplement Fig. 4 B,C) ; an accurate IC50 could not be determined for u-MEK due to its low kinase activity. This suggests that the additional phosphorylation of S217 on the MEK1 activation loop reduces the binding affinity of MEK1 for GSK1120212 presumably by altering the compound binding site.
To investigate whether GSK1120212 inhibited MEK1 phosphorylation at S217 in cells, A549 and A-375P(F11) cells were treated with 250 nM compound for 0, 6, 24, 48 and 72hrs. MEK1 was immunoprecipitated and phosphorylation on S217 and S221 was monitored by mass spectrometry. As we observed by immunoblot analysis, phospho-S221 levels gradually increased in both A549 and A-375P(F11). In contrast, S217 phosphorylation decreased upon treatment with GSK1120212 and showed no increase over time. (Fig.2C, D) . These results are consistent with both our observation of a feedback response increase in MEK phosphorylation and the in vitro biochemical assay findings that GSK1120212 decreased phosphorylation of MEK1 at S217. We conclude that GSK1120212 fully inhibits MEK activity and partially inhibits MEK activation by Raf.
Since GSK1120212 does not directly inhibit either C-Raf or B-Raf activity in enzymatic
on July 15, 2017. © 2011 American Association for Cancer clincancerres.aacrjournals.org Downloaded from assays, we believe that GSK1120212 must bind to MEK in a way that specifically blocks the accessibility of S217 to Raf kinases.
Profiling cells sensitive to GSK1120212
To evaluate the therapeutic utility of GSK1120212 in cancers with various mutational profiles, we conducted 72hr proliferation assays on a panel of cell lines. For our analysis we considered the curve parameters gI 50 (concentration resulting in 50% growth inhibition) indicating the effective biological drug concentration and the Ymin (% cell number at the maximum effective dose relative to that at Time-0) indicating the achievable biological effect. The growth and apoptotic response of two cell lines, SK-MEL-28 (BRAF V600E ) and A549 (KRAS G13D ), were compared in more detail with daily cell growth curves (CellTiter-Glo). In SK-MEL-28 cells (Fig. 3A) , GSK1120212 caused minimal effect on growth within 24hrs, but caused a clear net cell decrease (Ymin= -70% at 72hrs) at 48 and 72hrs. By comparison, in A549 cells (Fig. 3B ) GSK1120212 caused primarily growth inhibition (Ymin =182% at 72hrs). These results indicate that MEK inhibition can produce a time-dependent delay in growth and that the effect on net cell survival can vary across cell lines according to their intrinsic sensitivity.
We applied this analysis of proliferation assay curves across 94 cancer cell lines, evaluating sensitivity to GSK1120212 based on the gI 50 and Ymin. The latter parameter was used to define cell response as cytotoxic (net cell loss), cytostatic (< 1 net cell doubling), or less than cytostatic (>1 net cell doubling). Among the cell lines tested, those with the BRAF V600E mutation represented the most sensitive group of cells. Of the BRAF V600 mutant cells 10/10 had gI 50 below 50 nM GSK1120212 (Fig. 3C) , and 7/10 cells had cytotoxic response (Fig. 3D) . Among the other cell lines that showed the greatest sensitivity to GSK1120212, the predominant determinants were activating mutations in
KRAS or NRAS. Among cell lines with activating KRAS mutation (specifically alterations in
Research. Fig. 4A; Supplementary Fig.5 ). The data demonstrate that on day 1 a single dose of GSK1120212 significantly reduces ERK phosphorylation for >8hrs. We further observe that blood levels of GSK1120212 accumulate following multiple drug administrations (with steady state being reached on day 4; data not shown). As a consequence of the higher steady state levels of GSK1120212, inhibition of p-ERK is greater following the day 7 dose with reduced p-ERK levels sustained over 24hrs. The sustained inhibition of ERK phosphorylation is consistent with the pharmacokinetic (PK) profile in blood, which was characterized by a gradual increase in GSK1120212 blood concentration to the Cmax (Cmax average: 1410 nM at 4.0hrs day 7), followed by a gradual decline in concentrations, resulting in a long effective half-life (Day 7 est. mean T-½: 33hrs). Brain samples showed no inhibition of ERK phophorylation, with low levels of GSK1120212 detected at day 7 in the brain (Supplementary Fig.5 ).
Research. 
By immunohistochemistry (IHC) of the tumors, we confirmed both the immediate inhibition of ERK phosphorylation as well as the longer-term anti-proliferative activity.
Consistent with the p-ERK ELISA results, IHC staining for ERK phosphorylation (diphospho ERK1/2) confirmed significant inhibition 4hrs after doses 1 and 4 with 3mg/kg GSK1120212 (Fig. 5) . Additionally, IHC staining for levels of Ki67 and p27 Kip1/CDKN1B (markers of cell proliferation and cell cycle arrest, respectively) confirmed inhibition of cell proliferation (reduced Ki67) and G1 cell cycle arrest (elevated p27 Kip1/CDKN1B ) following 4 days GSK1120212 treatment.
To evaluate the PK profile of GSK1120212 in more detail, repeat dose PK studies were also conducted in rats. Female rats were orally dosed with 1.0mg/kg GSK1120212 for 3 weeks (n=3 rats). Following the day 1 and 21 doses, blood was drawn serially at timepoints extending to 24hrs (Fig. 4B) . Consistent with the mouse data, we observed on each day a gradual increase of GSK1120212 concentrations in plasma to the Cmax Fig.6A) .
Although treatment with GSK1120212 caused significant tumor growth delay and some regressions, A-375P(F11) tumors generally resumed growth when drug treatment was interrupted (data not shown). Similarly in the KRAS-mutant HCT 116 xenograft model, GSK1120212 caused significant tumor growth inhibition at 1.0 or 3.0mg/kg doses (Fig.6B) .
GSK1120212 was tested for activity in multiple additional tumor xenograft models with activating mutations in BRAF, KRAS, or neither (Supplementary Fig.6 ) and demonstrated antitumor activity in all models. In all experiments, 3.0mg/kg GSK1120212 was orally administered daily for 14 days, and tumor growth inhibition (TGI) was determined in comparison to the vehicle treated tumors at the time when mean tumor size exceeded 1000 mm 3 . Among the xenograft lines tested, the BRAF-mutant Colo205, A-375P(F11) and HT29 models showed the most significant mean tumor growth inhibition (85%, 80%, and 87% TGI) with multiple complete and partial tumor regressions. Two KRAS mutant xenograft models, HCT-116 and A549, also showed significant tumor growth inhibition (83% and 75% TGI) but without significant tumor regressions. As predicted by cell proliferation assays, tumor xenograft lines with wild-type RAF/RAS (PC3, BxPC3 and BT474) were relatively much less sensitive, showing only modest tumor growth inhibition with no tumor regressions (46%, 45%, and 44% TGI).
Discussion:
Past studies of other allosteric MEK inhibitors have expressed conflicting results as to their ability to inhibit Raf phosphorylation of MEK (20) (21) (22) (23) . While this may reflect real differences in the mechanism of action for different compounds, it likely also reflects the technique used for measuring MEK activation. Most commercial phospho-MEK1/2 antibodies do not differentiate between mono-and di-phosphorylated MEK, but these represent significantly different activation states (19) . GSK1120212 inhibition of S217 phosphorylation contributes to the overall inhibition of MEK. At high concentration Multiple MEK inhibitors have now failed to show significant efficacy in clinical trials. CI-1040 produced a range of now recognizable on-target adverse events including skin rash, edema, and diarrhea (31), but unpromising activity. PD0325901 was discontinued due in part to toxicities that included retinal vein occlusions and neuropathy that apparently reflected intolerable drug levels passing the blood barriers of the retina and central nervous system; these toxicities were subsequently modeled in animal models where PD0325901 caused RVO in rabbits (32) and inhibition of p-ERK in the brain (33) .
We demonstrated that GSK1120212 does not significantly penetrate intact brain nor Both PD0325901 and more recently AZD6244 (Arry-142886) showed promising inhibition of ERK phosphorylation in a subset of melanoma patients, but these failed to translate into improved patient outcome in single agent trials (34) (35) (36) (37) (38) . A leading interpretation is that previous MEK inhibitor compounds have not achieved the developability properties required to produce in vivo concentrations that remain within the narrow therapeutic window, raising the question of whether this goal is in fact achievable.
GSK1120212 is orally bioavailable, exceptionally potent and specific, and has a long halflife with a shallow Cmax to Ctrough pharmacokinetic profile. These characteristics suit the profile for an inhibitor of tumors dependent on activating mutations in the MAPK pathway, especially those harboring activating mutations in KRAS and BRAF. Since growth inhibition by a MEK inhibitor is generally fully-reversible upon drug removal, the presumed optimal profile is a sustained steady-state drug concentration in excess of the dose required for activity. In contrast to multiple other MEK inhibitors that required twice-daily dosing in mice to achieve sustained or near-sustained MEK inhibition, GSK1120212 dosed daily at the repeat dose MTD achieves steady state blood levels that remain above 250 nM (5x our defined 'sensitive' concentration in cells) for 24hrs, causing sustained inhibition of p-ERK. We demonstrated that GSK1120212 does not significantly penetrate intact brain nor inhibit brain p-ERK, suggesting that brain penetration related toxicities may be avoidable by a favorable drug distribution profile. 
B. & C. MS Analysis of cellular MEK1 phosphorylation in A-375P(F11) (C) and A549 (D)
cells treated with 250nM GSK1120212 shows phospho-S221 (black) levels increased in both cell lines at later timepoints; in contrast, phospho-S217 (gray) levels decreased to limit of detection. A. Cells were treated with titrations of GSK1120212 to conduct 72hrs cell growth assays using CellTiter-Glo reagent. In highly-sensitive SKMEL-28 cells (BRAF V600E ), GSK1120212 initially causes a slight growth delay within 24hrs, with increased net cell death evident by 48 and 72hrs.
Research. Blood levels increased after day 1, reaching steady-state levels by day 4 (data not shown). In mice, the mean apparent half-life in blood was ~33hrs.
B. More detailed pharmacokinetic analysis of plasma levels GSK1120212 in female SD rats dosed daily at 1.0mg/m 2 (n=3 per day). Serial draws on Day1 and Day21 reveals a gradual increase in plasma concentration, shallow Cmax, and gradual decrease, resulting in drug accumulation. The mean apparent half-life in rats was ~36hrs B.&C. MEK1 kinase assays were carried out using 1nM pp-MEK1(S217/S221) or 5 nM p-MEK1(S221), determined to be approximately the lowest concentrations that gave a sufficient assay signal. Kinase assays, were conducted as previously described using kinase-dead ERK2 as substrate with 33P-γATP detection in TCA precipitation filter binding assay. Notably, the measured IC50 for GSK1120212 against p-MEK1(S221) is 2.5nM or ~1/2 the enzyme concentration (5nM); since we cannot accurately measure IC50 below 1/2 x [enzyme], the true IC50 for GSK1120212 against p-MEK1(S221) may be lower than 2.5nM. Therefore, the average IC50 of GSK1120212 against pp-MEK1(S217/S221) was at least 6-fold higher than against pMEK1(S221).
on 250nM GSK1120212 shows phospho-S221 (black) levels increased in both cell lines at later timepoints; in contrast, phospho-S217 (gray) levels decreased to limit of detection. 
